The Nuclear Medicine Department would like to offer a new therapy to their patients with prostate cancer.  However, to offer this treatment, refurbishment of the existing therapy rooms and waiting area is needed.

Lutetium-177 (177Lu)-PSMA-617 is a new innovative therapy, where a radioactive dose is injected into the patient, targeting the disease and treating it directly, unlike chemotherapy, which treats the body as a whole.

This new space will allow the patients to receive their treatment as a ‘day case’, rather than needing to stay in the ward overnight.